Antisoma leukaemia treatment to be fast-tracked Thu 03 Jun 2010
LONDON (SHARECAST) - Cancer drug developer Antisoma’s Leukaemia treatment AS1413 has been granted Fast Track designation by the US Food and Drug Administration (FDA).
The Fast Track programme affords drugs that have shown the potential to meet an unmet medical need in serious or life-threatening diseases a speedier review process than would otherwise be the case.
‘We're very pleased to have gained FDA Fast Track status for AS1413,’ said Antisoma chief executive Glyn Edwards.
‘This drug could represent a major advance in the options available to patients with secondary AML [acute myeloid leukaemia], and we look forward to completing the ongoing phase III trial and sharing the data with FDA and other regulators.’
At the ASCO meeting we will have three presentations on AS1411, including updated findings from the first phase II clinical trial in AML and data from a phase II clinical trial in renal cancer.
Three presentations with relevance to AS1413 will be made at the American Society of Clinical Oncology (ASCO) Annual Meeting in June; abstracts will be available on the ASCO website (www.asco.org) from 20 May.
ich hab jetzt eh keine zeit, da im moment wamu absolute priorität hat. ich schau gegen abend mal wieder rein. ich hoffe, dann haben wir schon die 0,10€. :D
----------- der gewinner hat viele freunde, der verlierer nur gute!
Thread abonnieren
